Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

http://www.wikidata.org/entity/Q33881750

about

Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808 Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.Performance status in elderly patients with acute myeloid leukemia: exploring gene expression signatures of cytokines and chemokines.Common gamma chain cytokines in combinatorial immune strategies against cancer The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Acute myeloid leukemia: focus on novel therapeutic strategies.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.Immunotherapy in acute myeloid leukemia.Antibody-Based Treatment of Acute Myeloid Leukemia.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients.Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML).TNFR2: The new Treg switch?Posttreatment interleukin-2 in patients with acute myeloid leukemia: the end of a long road for patients and clinical trials?Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

P2860

Q24187927-16F514EF-237C-4B97-AD44-196818937218 Q24202630-0A7D8C11-29C4-4FEB-A95F-88484B83F69C Q30249246-A51D6014-4AEA-4C22-B876-8AB12D030BED Q33423753-F57CC935-7C02-420A-92AB-A270B72D0192 Q34069811-F4AE9BB5-BAF3-4639-9F79-4DDDAFAC1EE3 Q34563034-53BCF4EE-CBC3-4237-9EE8-0486595F80AF Q35661799-4567F3E9-2F77-43BF-9881-457BB9AE0E03 Q36455872-CB7FB2DA-9256-4D5C-B145-72D9251C7FAC Q37517482-EE9D6880-E534-49CC-B5F3-577508A5F11B Q37558778-08BBDB3C-EF8A-4616-A0F4-F7C7CB036F7D Q37624593-9C243278-9439-4D9C-B679-668691C62D9F Q38015336-98A1A95D-5EBE-4EEE-8DEC-6099DB7D6F14 Q38104287-4E9AE494-AB24-450A-88E6-DF47AB3ABF78 Q38208953-DDFA1FC6-1B76-4120-AF4B-359A86E75BED Q38533606-4965DAD4-771A-482B-9804-F19DBE504ADC Q38979277-F9BA4F48-2E0E-4C47-AB03-737DD53982B5 Q39100229-23BB0A70-C253-4893-83E0-5EC317965F6B Q41269711-6AFE43D4-259C-4F2A-A005-AAD78A25C720 Q41527981-DF078907-8A7C-49D4-AA78-0B32797D8FC8 Q45033088-52336547-0866-429C-8CC3-4E40259515D5 Q47381937-E8E2305E-1BE4-46FB-8B68-9615BB7972E3 Q54379778-68FD17BE-78FF-41A0-9357-BFEADD6DC7EE Q55397325-FEA785C2-9A78-4A65-A8E9-2C6321803299

P2860

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

http://www.wikidata.org/entity/Q33881750

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@ast

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@en

type

label

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@ast

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@en

prefLabel

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@ast

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@en

P1433

Q33881750-6D0293EC-AA5E-4DBA-83D8-E92528F762E5

P1476

Q33881750-3C5BC2B1-A52C-4EE6-8A35-89DE8442E503

P2093

Q33881750-15C10414-8B14-482E-8F9A-5374406F86F8

Q33881750-5CBADA57-4625-4CF8-B8D1-0829BA57660D

Q33881750-62C4B384-CBD8-4D46-BCAA-593A8F8AD783

Q33881750-6ABDCF3E-007E-48A4-9CB4-18674CA3A9B6

Q33881750-7ED50912-EECD-45E2-A9A0-DF55DD30D07E

Q33881750-A515EB2B-4061-4E3E-A4F5-80C33EE9B5BD

Q33881750-A62D630A-CD2B-4F9D-BB31-8E83D0487CE1

Q33881750-B98C41B0-BC23-4833-9BFA-EE0722F8B0B9

Q33881750-D7DF1D52-C0CB-4558-8C84-E4DC843C749D

P2860

Q33881750-0A7A2115-975B-41DE-8302-1FE2D5425FD8

Q33881750-271FDDFF-20DF-495B-8D30-22BC00A4E8A1

Q33881750-2AD12F32-A1E7-490A-8E88-6D34BA3D074A

Q33881750-2C16B67F-4B11-479B-BF51-0885EFA3F3F2

Q33881750-390D87C9-F443-4B8F-A219-CF9237B8A974

Q33881750-3988AC31-34B2-4833-89C8-1A4717BCA66A

Q33881750-3BC61550-B764-48B2-8109-C9875F87C9DA

Q33881750-42F568BC-3933-4276-BB22-98F4C994459E

Q33881750-495606C9-E5C3-41A5-94E5-D73AAFFE849A

Q33881750-5C6D73B4-1C17-4295-9ADB-E794FE9EC6F2

P304

Q33881750-7AB14453-7CC1-4B2A-9143-150992890C6A

P31

Q33881750-102837CF-09B4-429F-8F34-8E75A87A21C7

Q33881750-c831904f-d8b7-4e05-993a-b0a2afebdd82

P356

Q33881750-D94ACE85-4486-4407-91F7-D26D90F2BCE3

P407

Q33881750-7BBF9A9D-5620-40BC-91B5-BEA6181A14A6

P433

Q33881750-77D4B367-BF2B-4B28-9671-20701BC4A1AC

P478

Q33881750-24E8A338-3816-47DD-B4A1-D81AD6C1C065

P50

Q33881750-44500E88-CCCE-4296-A9A6-6E7431D34E8B

Q33881750-77CED722-C19A-4DB6-BABF-DCEEA6DA7B90

Q33881750-B95A33DE-ECB1-4179-BF1C-1A82FF2507AB

Q33881750-CF0CEBFD-4C4C-4E31-A298-1C5AFBBE986C

Q33881750-E6E3529C-8EB3-48C6-AC81-75574215EE7C

P577

Q33881750-06D3C689-D3E9-4BF0-BA58-2D2909798FFA

P5875

Q33881750-20E17F76-9C96-48F2-840C-DEF78D82AF73

P698

Q33881750-A53032BF-6019-4B0E-BBE6-AF919D862173

P921

Q33881750-04AA0310-842A-49DF-812C-FDB168D5E151

Q33881750-9F61013A-19DB-4A9E-9CDC-1192B8B1CEAF

P932

Q33881750-CF5A8AE2-0B10-4EAB-8BD4-61AB67786507

P356

BLOOD-2011-02-337725

P1433

P1476

Individual patient data meta-a ...... apy in acute myeloid leukemia.

@en

P2093

Beverly J Lange

http://www.w3.org/2001/XMLSchema#string

Didier Blaise

http://www.w3.org/2001/XMLSchema#string

Dominique Maraninchi

http://www.w3.org/2001/XMLSchema#string

Jonathan E Kolitz

http://www.w3.org/2001/XMLSchema#string

Kathryn J Lucchesi

http://www.w3.org/2001/XMLSchema#string

Pierre Squifflet

http://www.w3.org/2001/XMLSchema#string

Stephen L George

http://www.w3.org/2001/XMLSchema#string

Sylvie Castaigne

http://www.w3.org/2001/XMLSchema#string

Todd A Alonzo

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.

P304

7007-7013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-337725

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Larson

Clara D. Bloomfield

Tomasz Burzykowski

P577

2011-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51075885

http://www.w3.org/2001/XMLSchema#string

P698

21518931

http://www.w3.org/2001/XMLSchema#string

P921

P932

3539044

http://www.w3.org/2001/XMLSchema#string